Skip to main content

Table 1 Comparisons of clinicopathologic and treatment characteristics by era

From: Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras

Characteristics

Pre-Trastuzumab Era

Trastuzumab Era

p- value

 

n = 128

n = 441

 

Age (years)

0.017

  <65

104 (81%)

345 (78%)

  ≥ 65

24 (19%)

96 (22%)

  Median

53 (26–81)

55 (29–91)

M1 at diagnosis

<0.001

  Yes

5 (4%)

113 (26%)

  No

115 (90%)

256 (58%)

  Unknown

8 (6%)

72 (16%)

Tumor grade

0.084

  1

0 (0%)

13 (3%)

  2

24 (19%)

106 (24%)

  3

95 (74%)

315 (71%)

  Unknown

9 (7%)

7 (2%)

Hormone receptor status

0.83

ER+

51 (40%)

180 (41%)

ER-

68 (53%)

249 (57%)

Unknown

9 (7%)

12 (3%)

HER2 status

<0.001

  Positive

33 (26%)

176 (40%)

  Negative

87 (68%)

212 (48%)

Unknown

8 (6%)

53 (12%)

Time from diagnosis to BM (years)

 

  Median

3.3

2.3

 

KPS at BM

0.76

  <70

47 (37%)

170 (38%)

  ≥70

81 (63%)

271 (62%)

Number of BM

0.025

  1

44 (34%)

117 (27%)

  2-3

23 (18%)

73 (16%)

  Multiple

61 (48%)

251 (57%)

Primary disease at BM

0.007

  Controlled

104 (81%)

305 (70%)

  Uncontrolled

24 (19%)

135 (31%)

Extracranial disease at BM

0.32

  Brain only

22 (17%)

97 (22%)

  Bone + brain

22 (17%)

76 (17%)

  Visceral + brain +/−bone

76 (59%)

245 (57%)

  Other

8 (6%)

23 (5%)

RPA at BM

0.17

  1

9 (7%)

55 (12%)

  2

72 (56%)

219 (50%)

  3

47 (37%)

167 (39%)

Craniotomy

0.037

  Yes

15 (12%)

87 (20%)

No

113 (88%)

354 (80%)

Trastuzumab at BM*

 

  Yes

0 (0%)

150 (34%)

 

  No

128 (100%)

26 (5%)

 

Hormonal therapy at BM*

<0.001

  Yes

72 (56%)

100 (23%)

  No

56 (44%)

341 (77%)

Chemotherapy at BM*

0.032

  Yes

43 (34%)

194 (44%)

  No

85 (66%)

242 (55%)

  Unknown

0 (0%)

5 (1%)

  1. * Refers to treatments given on or after the date of first brain metastases.
  2. Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, KPS = Karnofsky performance status, BM = brain metastasis, RPA = recursive partitioning analysis.